Pegylated liposomal doxorubicin: An efficient treatment in patients with Hodgkin lymphoma relapsing after high dose therapy and stem cell transplation

British Journal of Haematology

Volumn 162, Issue 6, 2013, Pages 846-848

  Clozel, Thomas ^a   Deau, Benedicte ^a   Benet, Claire ^b   Franchi, Patricia ^b   Robin, Marie ^b   Madelaine, Isabelle ^b   Thieblemont, Catherine ^b   de Kerviler, Eric ^b   Brière, Josette ^b   Brice, Pauline ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Drugs; High dose therapy; Hodgkin lymphoma

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; PREDNISONE; PROCARBAZINE; VINCRISTINE; VINCRISTINE SULFATE;

ADOLESCENT; ADULT; ALLOTRANSPLANTATION; ALOPECIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HAND FOOT SYNDROME; HEART EJECTION FRACTION; HEMATOLOGIC DISEASE; HODGKIN DISEASE; HUMAN; LETTER; LEUKEMIA; LONG TERM SURVIVAL; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SALVAGE THERAPY;

DRUGS; HIGH DOSE THERAPY; HODGKIN LYMPHOMA;

ADOLESCENT; ADULT; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYETHYLENE GLYCOLS; RECURRENCE; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; YOUNG ADULT;

EID: 84883287314     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12428     Document Type: Letter

References (9)

1. Bartlett, N.L., Niedzwiecki, D., Johnson, J.L., Friedberg, J.W., Johnson, K.B., van Besien, K., Zelenetz, A.D., Cheson, B.D. & Canellos, G.P. (2007) Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO, 18, 1071-1079.
2. Brice, P. (2008) Managing relapsed and refractory Hodgkin lymphoma. British Journal of Haematology, 141, 3-13.
3. Gabizon, A.A. (2001) Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Investigation, 19, 424-436.
4. Moskowitz, A.J., Hamlin, P.A. Jr, Perales, M.-A., Gerecitano, J., Horwitz, S.M., Matasar, M.J., Noy, A., Palomba, M.L., Portlock, C.S., Straus, D.J., Graustein, T., Zelenetz, A.D. & Moskowitz, C.H. (2013) Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31, 456-460.
5. Pulini, S., Rupoli, S., Goteri, G., Pimpinelli, N., Alterini, R., Bettacchi, A., Mulattieri, S., Picardi, P., Tassetti, A., Scortechini, A.R., Fioritoni, G. & Leoni, P. (2009) Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies. European Journal of Haematology, 82, 184-193.
6. Quereux, G., Marques, S., Nguyen, J.-M., Bedane, C., D'incan, M., Dereure, O., Puzenat, E., Claudy, A., Martin, L., Joly, P., Delaunay, M., Beylot-Barry, M., Vabres, P., Celerier, P., Sasolas, B., Grange, F., Khammari, A. & Dreno, B. (2008) Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Archives of Dermatology, 144, 727-733.
7. Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A.M., Haenel, M., Boissevain, F., Zschaber, R., Müller, P., Kirchner, H., Lohri, A., Decker, S., Koch, B., Hasenclever, D., Goldstone, A.H. & Diehl, V. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet, 359, 2065-2071.
8. Sureda, A., Robinson, S., Canals, C., Carella, A.M., Boogaerts, M.A., Caballero, D., Hunter, A.E., Kanz, L., Slavin, S., Cornelissen, J.J., Gramatzki, M., Niederwieser, D., Russell, N.H. & Schmitz, N. (2008) Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 26, 455-462.
9. Younes, A., Gopal, A.K., Smith, S.E., Ansell, S.M., Rosenblatt, J.D., Savage, K.J., Ramchandren, R., Bartlett, N.L., Cheson, B.D., de Vos, S., Forero-Torres, A., Moskowitz, C.H., Connors, J.M., Engert, A., Larsen, E.K., Kennedy, D.A., Sievers, E.L. & Chen, R. (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 30, 2183-2189.